Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SMMT
  • CUSIP:
Key Metrics:
  • Previous Close: $11.90
  • 50 Day Moving Average: $10.6384
  • 200 Day Moving Average: $9.5896
  • 52-Week Range: $4.26 - $19.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.72
  • P/E Growth: 0.0000
  • Market Cap: $147.12M
  • Outstanding Shares: 12,363,000
  • Beta: 0.12
Profitability:
  • Return on Equity: -161.52%
  • Return on Assets: -82.65%
Debt:
  • Current Ratio: 3.85%
  • Quick Ratio: 3.85%
Additional Links:
Companies Related to Summit Therapeutics PLC:

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.67 (132.50% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetDetails
2/1/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$28.00 -> $24.00View Rating Details
11/16/2016RBC Capital MarketsBoost Price TargetOutperform$26.00 -> $29.00View Rating Details
11/16/2016Royal Bank Of CanadaBoost Price TargetOutperform$26.00 -> $29.00View Rating Details
10/24/2016Canaccord GenuitySet Price TargetBuy$28.00View Rating Details
10/4/2016Needham & Company LLCBoost Price TargetBuy$22.00 -> $30.00View Rating Details
9/16/2016HC WainwrightInitiated CoverageBuy$26.00View Rating Details
6/21/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details
4/2/2015JMP SecuritiesInitiated CoverageOutperform$32.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/27/2015Q215($0.06)($0.55)ViewListenView Earnings Details
6/11/2015Q115($0.06)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
Current Year EPS Consensus Estimate: $-2.2400 EPS
Next Year EPS Consensus Estimate: $-1.1100 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.78)($0.78)($0.78)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.50)($0.50)($0.50)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
DateHeadline
finance.yahoo.com logoSummit Therapeutics to Participate in February Investor Conferences (NASDAQ:SMMT)
finance.yahoo.com - February 3 at 5:15 AM
News IconWhat We’re Looking For From Summit Therapeutics PLC (ADR) (SMMT) (NASDAQ:SMMT)
feedproxy.google.com - February 2 at 12:30 PM
globenewswire.com logoSummit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole (NASDAQ:SMMT)
globenewswire.com - February 2 at 2:50 AM
proactiveinvestors.co.uk logoSummit soars as it outlines phase III designs for its C. Diff treatment (NASDAQ:SMMT)
www.proactiveinvestors.co.uk - February 2 at 2:50 AM
us.rd.yahoo.com logoSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings (NASDAQ:SMMT)
us.rd.yahoo.com - February 2 at 2:50 AM
seekingalpha.com logoHealthcare Summit On The Eve Of Trump's New Deal: Milligan's Mea Culpa (NASDAQ:SMMT)
seekingalpha.com - January 24 at 2:28 AM
News IconSchool Choice: finding what works for your child (NASDAQ:SMMT)
newsms.fm - January 24 at 2:28 AM
4-traders.com logoPain Therapeutics : Agenda Released for 17th Annual Pain Therapeutics Summit Featuring Nektar, MSD USA, Janssen, Grunenthal and AstraZeneca (NASDAQ:SMMT)
www.4-traders.com - January 23 at 9:26 PM
News IconThird Annual Washington Cannabis Summit Review (NASDAQ:SMMT)
www.ganjapreneur.com - January 23 at 9:26 PM
News IconCyclist plunges off 300ft cliff along Bolivia's Death Road after losing control of her bike... but miraculously SURVIVES after landing on a tiny ledge (NASDAQ:SMMT)
www.dailymail.co.uk - January 23 at 8:31 AM
News IconKaiser Permanente Pharmacy Locations - Herbal Pharmacy - Liss Pharmacy Summit Nj - 2,507 Completed ORDERS Today! (NASDAQ:SMMT)
www.netnewsledger.com - January 22 at 7:36 PM
News IconLiss Pharmacy Summit Nj - Walmart Pharmacy El Paso Tx - Bjs Pharmacy - 6,480 Completed ORDERS Today! (NASDAQ:SMMT)
www.thevegspace.co.uk - January 22 at 8:07 AM
News Icon2017 Legislative Summit to provide veterans with information about upcoming legislative session (NASDAQ:SMMT)
carsonnow.org - January 22 at 12:42 AM
News IconHerbal Pharmacy - Liss Pharmacy Summit Nj - Walmart Pharmacy El Paso Tx - 8,880 Completed ORDERS Today! (NASDAQ:SMMT)
blog.heartland.org - January 22 at 12:42 AM
News IconAgenda Released for 17th Annual Pain Therapeutics Summit Featuring Nektar, MSD USA, Janssen, Grunenthal and AstraZeneca (NASDAQ:SMMT)
satprnews.com - January 21 at 7:38 PM
News IconOver 90 pct of HIV patients in Nigeria's oil rich state not on medication (NASDAQ:SMMT)
news.xinhuanet.com - January 21 at 1:24 AM
News IconLiss Pharmacy Summit Nj - Walmart Pharmacy El Paso Tx - Bjs Pharmacy - 1,609 Completed ORDERS Today! (NASDAQ:SMMT)
www.littlesunnykitchen.com - January 21 at 1:24 AM
News IconA/Ibom says 262,447 HIV patients are without drugs (NASDAQ:SMMT)
thenewsnigeria.com.ng - January 21 at 1:24 AM
News IconSummit Appoints Dr David Roblin as Chief Operating Officer and (NASDAQ:SMMT)
www.biomedreports.com - January 19 at 4:41 PM
News IconPublic meeting on Summit Pacific “Wellness Center” planned for this week (NASDAQ:SMMT)
www.kxro.com - January 19 at 4:41 PM
News IconSummit Therapeutics appoints David Roblin as COO (NASDAQ:SMMT)
www.poandpo.com - January 19 at 4:41 PM
News IconScots Pavilion (NASDAQ:SMMT)
www.penangpropertytalk.com - January 19 at 4:41 PM
streetinsider.com logoAyretrade, Inc. (SUMM) Appoints David Roblin as COO (NASDAQ:SMMT)
www.streetinsider.com - January 18 at 11:04 PM
proactiveinvestors.co.uk logoSummit Therapeutics hires new COO as it advances to late-stage trials (NASDAQ:SMMT)
www.proactiveinvestors.co.uk - January 18 at 11:04 PM
us.rd.yahoo.com logoSummit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development (NASDAQ:SMMT)
us.rd.yahoo.com - January 18 at 11:04 PM
bizjournals.com logoSarepta eyes a different approach to Duchenne: gene therapy (NASDAQ:SMMT)
www.bizjournals.com - January 10 at 11:14 PM
bizjournals.com logoCambridge's Akashi plans clinical tests of three Duchenne drugs this year (NASDAQ:SMMT)
www.bizjournals.com - January 7 at 4:41 AM
News IconPost Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta - Yahoo Sports (NASDAQ:SMMT)
sports.yahoo.com - December 29 at 12:46 AM
4-traders.com logoSummit Therapeutics PLC : Post Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta (NASDAQ:SMMT)
www.4-traders.com - December 27 at 9:06 AM
finance.yahoo.com logoPost Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta (NASDAQ:SMMT)
finance.yahoo.com - December 27 at 9:06 AM
News IconToday's UK Stock Pattern Alert: Summit Therapeutics PLC (SUMM) Rises 4.41% on Dec 20 - Herald KS (NASDAQ:SMMT)
heraldks.com - December 20 at 2:43 PM
capitalcube.com logoSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 20, 2016 (NASDAQ:SMMT)
www.capitalcube.com - December 20 at 2:43 PM
baystreet.ca logoSummit Therapeutics (SMMT) Slip Before Earnings (NASDAQ:SMMT)
www.baystreet.ca - December 16 at 4:00 AM
cnbc.com logoSummit Therapeutics reports 3Q loss (NASDAQ:SMMT)
www.cnbc.com - December 16 at 4:00 AM
globenewswire.com logoSummit Therapeutics plc : 3rd Quarter Results (NASDAQ:SMMT)
globenewswire.com - December 16 at 4:00 AM
us.rd.yahoo.com logoSummit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress (NASDAQ:SMMT)
us.rd.yahoo.com - December 16 at 4:00 AM
us.rd.yahoo.com logo7:06 am Summit Therapeutics reports Q3 results; Phase II proof of concept DMD data expected mid-2017 (NASDAQ:SMMT)
us.rd.yahoo.com - December 16 at 4:00 AM
feeds.benzinga.com logoEarnings Scheduled For December 15, 2016 (NASDAQ:SMMT)
feeds.benzinga.com - December 15 at 6:21 AM
News IconSummit Therapeutics Plc (SMMT) Valuation According To Analysts - UK Market News (NASDAQ:SMMT)
www.ukmarketnews.co.uk - December 15 at 1:15 AM
lse.co.uk logoSummit Therapeutics plc : Notice of Results - Regulatory News, RNS ... - London South East (registration) (blog) (NASDAQ:SMMT)
www.lse.co.uk - December 14 at 1:38 AM
News IconSummit Therapeutics plc : Notice of Results - PharmiWeb.com (press release) (NASDAQ:SMMT)
www.pharmiweb.com - December 13 at 8:33 PM
finance.yahoo.com logoSummit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016 (NASDAQ:SMMT)
finance.yahoo.com - December 13 at 8:33 PM
News IconSummit Therapeutics Plc (NASDAQ:SMMT) Broker Views On Wall Street - NewsDen (NASDAQ:SMMT)
newsden.net - November 24 at 10:52 AM
News IconMarket Rating: 148.08% to Target, RBC Capital Markets Reaffirms Outperform Rating for Summit Therapeutics PLC ... - Thorold News (NASDAQ:SMMT)
www.whatsonthorold.com - November 17 at 11:46 AM
globenewswire.com logoSummit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (NASDAQ:SMMT)
globenewswire.com - November 16 at 11:18 AM
proactiveinvestors.co.uk logoSummit Therapeutics recruits for US leg of PhaseOut study (NASDAQ:SMMT)
www.proactiveinvestors.co.uk - November 16 at 11:18 AM
publicnow.com logoSummit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD (NASDAQ:SMMT)
www.publicnow.com - November 16 at 11:18 AM
News IconSummit Therapeutics Plc (NASDAQ:SMMT) – Broker Update - NewsDen (NASDAQ:SMMT)
newsden.net - November 10 at 10:52 AM
finance.yahoo.com logo4:47 pm Correction: Summit Materials (SUM (NASDAQ:SMMT)
finance.yahoo.com - November 9 at 7:34 PM
News IconAnalyst Coverage: Summit Therapeutics Plc (NASDAQ:SMMT) - NewsDen (NASDAQ:SMMT)
newsden.net - November 8 at 7:24 PM

Social

What is Summit Therapeutics PLC's stock symbol?

Summit Therapeutics PLC trades on the NASDAQ under the ticker symbol "SMMT."

Where is Summit Therapeutics PLC's stock going? Where will Summit Therapeutics PLC's stock price be in 2017?

7 brokerages have issued 12 month price targets for Summit Therapeutics PLC's stock. Their forecasts range from $24.00 to $30.00. On average, they anticipate Summit Therapeutics PLC's stock price to reach $27.67 in the next twelve months.

Who owns Summit Therapeutics PLC stock?

Summit Therapeutics PLC's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Lansdowne Partners UK LLP (7.52%).

How do I buy Summit Therapeutics PLC stock?

Shares of Summit Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Summit Therapeutics PLC stock cost?

One share of Summit Therapeutics PLC stock can currently be purchased for approximately $11.90.

Summit Therapeutics PLC (NASDAQ:SMMT) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)

Earnings History Chart

Earnings by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)

Dividend History Chart

Dividend Payments by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)

Last Updated on 2/22/2017 by MarketBeat.com Staff